Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | XMT-2056 |
Synonyms | |
Therapy Description |
XMT-2056 is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeting antibody conjugated to a STING agonist, which potentially induces an anti-tumor immune response and inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3503). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XMT-2056 | XMT2056|XMT 2056 | HER2 (ERBB2) Antibody 76 HER2 (ERBB2) Antibody-Drug Conjugate 31 STING1 Agonist 19 | XMT-2056 is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeting antibody conjugated to a STING agonist, which potentially induces an anti-tumor immune response and inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3503). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05514717 | Phase I | XMT-2056 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Recruiting | USA | 0 |